1,25-Dihydroxy-16-Ene-23-Yne-Vitamin D3.
Research-backed vitamin with potential health benefits. A laboratory-built vitamin D receptor ligand. Its rebuilt side chain resists the enzyme that clears active vitamin D, so researchers use it to study receptor signalling and calcium handling.
Reviewed March 2026
- Category
- Vitamin
What 1,25-Dihydroxy-16-Ene-23-Yne-Vitamin D3 is, and what it does.
- Does it work
- No. For the average person, this is a hard pass. It's a tool for scientists, not a daily supplement. Stick with standard Vitamin D3.
- How much to take
- Don't. There is no established consumer dose. Doses used in research are highly specific and administered under strict medical supervision.
- Time to feel it
- There's nothing to time in a supplement sense. It works through gene transcription, and researchers read it as calcium measures and cell markers over days.
- The first dose
- Zero. This works at the genetic level, a process that takes days to weeks to manifest.
- With regular use
- Unknown in humans outside of clinical trials. The goal in research is controlled cell growth and immune modulation, but long-term safety isn't established for public use.
- How well tolerated
- Safety profile is not well understood for general use. The main design feature is being less 'calcemic' (calcium-raising), but that doesn't make it harmless.
- How it feels
- You feel nothing. It's designed to change cellular behavior, not your mood or energy levels.
- The overlooked benefit
- It shows why analogue chemistry exists at all. Change two bonds in the tail and the same receptor is still engaged while the degrading enzyme has a harder time getting to work.
1,000 to 4,000 IU a day is where 1,25-Dihydroxy-16-Ene-23-Yne-Vitamin D3 works.
Source: Holick 2017 meta-analysis + Endocrine Society
The proof, claim by claim.
These words describe the research, not the molecule's worth. Research strength is how much work stands behind one claim, and it is never a product score.
1,25-Dihydroxy-16-Ene-23-Yne-Vitamin D3 is documented in the library; the clinical read is in the queue. Nothing about the strength of the research prints until the read is done.
- vitamin D receptor binding and transcriptional activityIn vitro study
- resistance to CYP24A1 degradationIn vitro study
- calcium handling relative to the parent metaboliteAnimal study
- cell differentiation in laboratory modelsIn vitro study
Questions people ask about 1,25-Dihydroxy-16-Ene-23-Yne-Vitamin D3.
- Is this better than regular Vitamin D?
- No, just different. It's a specialized tool for research. For 99.9% of people, regular Vitamin D3 is what you need.
- Can I buy this?
- Not as a consumer supplement. It's a research chemical. If you see it for sale, be extremely skeptical.
- Why was it made?
- To get some of Vitamin D's benefits, like controlling cell growth, without its main side effect at high doses: dangerously high blood calcium.
- Is it for bone health?
- Not primarily. It was designed specifically to have weak effects on calcium and bones compared to its other cellular effects.
- Are there any benefits for me?
- Unlikely and unproven for general health. The potential uses are for serious medical conditions and are still being studied.
- What's the '16-Ene-23-Yne' part mean?
- That's chemistry-speak for the specific modifications made to the standard Vitamin D molecule to change how it works in the body.
Why these belong in the same formula. Each row says what the basis is, from settled biochemistry through to a trial that measured the pair.
Cholecalciferol becomes calcitriol after two hydroxylations, and calcitriol is what occupies the vitamin D receptor. A synthetic 1,25-dihydroxy analogue arrives already in that active configuration and competes for the same receptor pocket. Stacking an analogue with a parent vitamin D means two ligands for one receptor, and no dietary supplement context has established what that combination does.
Calcitriol and its analogues raise expression of the calcium-binding and channel proteins that move dietary calcium across the intestinal epithelium. Analogues at the 16-ene and 23-yne positions were designed specifically to alter that calcium-handling profile relative to receptor activity. The relationship to calcium is the axis that defines this compound class.
The 25-hydroxylase and 1-alpha-hydroxylase steps are magnesium-dependent, as is the vitamin D binding protein interaction. An already-dihydroxylated analogue bypasses those steps, so the dependency applies to endogenous vitamin D rather than to the analogue itself. Magnesium status still governs the background vitamin D system the analogue acts within.
Vitamin D signalling raises calcium absorption and osteocalcin expression; vitamin K-dependent gamma-carboxylation is what allows those Gla proteins to bind calcium. The two act sequentially on mineral handling. This is established mineral biochemistry applied to a receptor ligand, not a tested combination for this analogue.
Calcitriol upregulates the NaPi-IIb intestinal phosphate transporter as well as the calcium machinery. Calcium and phosphate handling move together under vitamin D receptor control. An analogue's mineral profile is defined by how far it separates these effects from its other receptor actions.
VDR does not bind DNA alone; it partners with RXR, and 9-cis retinoic acid derived from vitamin A is the RXR ligand. Retinoid status therefore shapes the transcriptional output of any vitamin D receptor ligand. High retinoid exposure can also compete for shared RXR partners with other nuclear receptors. This is settled nuclear receptor biology.
Retinol is oxidised to retinoic acid, and the 9-cis isomer occupies RXR. The VDR-RXR heterodimer is the unit that binds vitamin D response elements. Analogue activity at VDR is read out through that same partnership.
Reported associations link boron intake with vitamin D metabolite levels, possibly through effects on the hydroxylase enzymes. The mechanism is not settled and the finding is associative. It applies to endogenous vitamin D metabolism rather than to a pre-hydroxylated synthetic analogue.
Nothing specific on file for 1,25-Dihydroxy-16-Ene-23-Yne-Vitamin D3. Match the label to the daily amount above, and tell your doctor what you take.
Not medical advice. Show the label to your pharmacist.What 1,25-Dihydroxy-16-Ene-23-Yne-Vitamin D3 actually does.
1,25-dihydroxyvitamin D3 is the hormonally active metabolite of cholecalciferol, produced by 25-hydroxylation in the liver followed by 1-alpha-hydroxylation, and it acts as a ligand for the nuclear vitamin D receptor.
The vitamin D receptor binds DNA as a heterodimer with the retinoid X receptor at vitamin D response elements, which is why retinoid status affects vitamin D transcriptional output.
CYP24A1 is the 24-hydroxylase that inactivates 1,25-dihydroxyvitamin D3, and its own expression is induced by vitamin D receptor occupancy, forming the feedback loop that limits active metabolite accumulation.
A pre-hydroxylated vitamin D analogue bypasses both the hepatic 25-hydroxylation and the renal 1-alpha-hydroxylation steps, so the physiological feedback that regulates conversion of dietary vitamin D does not apply to it.
Where 1,25-Dihydroxy-16-Ene-23-Yne-Vitamin D3 comes from.
Chemists start from a vitamin D-like molecule and rebuild parts of its tail, adding a double bond and a triple bond in specific places, then add two oxygen-containing groups. The result is a laboratory compound, not something extracted from food.
Chemically synthesised. The molecule is identical to the one a plant or an animal makes, and building it deliberately means a known purity, a fixed dose and no crop contaminants. For several nutrients this is the only route that reaches a usable amount.
Synthesis begins from a secosteroid precursor related to vitamin D, or from a steroid skeleton that can be opened to the secosteroid arrangement.
A 16-ene double bond is introduced into the D-ring region and a 23-yne triple bond into the side chain through multi-step chemistry, with stereochemistry controlled at each stage.
Hydroxyl groups are installed at the 1-alpha and 25 positions so the finished molecule arrives in the configuration that occupies the vitamin D receptor without needing metabolic activation.
Isomers and synthetic intermediates are separated chromatographically, since the biological behaviour of a secosteroid is highly sensitive to stereochemistry.
Identity and purity are confirmed spectroscopically and by chromatography against a reference standard.
The compound is handled as a laboratory reference material, protected from light and oxygen, which secosteroids are sensitive to.
The essence, in one line each.
- A review of synthetic vitamin D analogues, the 16-ene and 23-yne modified series among them, describing how structural changes at the side chain are intended to separate receptor activity from calcium handling; this is a preclinical and laboratory literature review, not human supplement evidence.Narrative review. Szyszka P et al., 2012 (Expert Review of Anticancer Therapy). PMID 22594894 ↗
These are the studies our verdict leans on, chosen from the 1 we read for 1,25-Dihydroxy-16-Ene-23-Yne-Vitamin D3. The full linked list is below.
FDA Disclaimer: These statements have not been evaluated by the Food and Drug Administration. This information is for educational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. Consult your healthcare provider before starting any supplement regimen.